Amarin Regains Ahead of Vital Q4 Catalysts Print E-mail
By Brian Williams - Lead Contributor   
Tuesday, 03 September 2013 08:45
Shares of Amarin Corporation (NASDAQ: AMRN) finally seem to be recovering from a prolonged selloff in July and August  – possibly on the “adequate” prescription sales data that has recently been coming through for the
company’s flagship drug Vascepa.
Read more...
 
Week Ending August 30 2013 Print E-mail
By Rajesh Patel, Ph.D.   
Tuesday, 03 September 2013 06:56
Biodel's upcoming data, Amgen talks about the

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

Onyx deal, Mannkind issues a FAQ, Catalyst gets breakthrough, ISIS presents data at PACE, CYTK data coming, Synergy schedules another annual meeting. Let's go over the stories we've been watching, commenting on and trading this week.
Read more...
 
Targeting an Untapped Female Sexual Dysfunction Drug Market Print E-mail
By Brian Wilson-Lead Contributor   
Thursday, 29 August 2013 01:02
The pharmaceutical industry remains extremely interested in female sexual dysfunction, primarily due to the enormous revenues that could be generated from this untapped US market.
Read more...
 
The Barker Brothers Increase Shares In Halozyme Director Makes Big Buy, Option Chain Heating Up Print E-mail
By Scott Matusow   
Wednesday, 28 August 2013 06:14
Often times, certain biotech institutional investors just seem to pick winner after winner, and stay on a hot streak -- so to speak. Baker Brothers LLC is one such institution that is becoming well-known and gaining great respect from the small cap biotech space.
Read more...
 
Biotech: A Scattershot of Stem Cell Plays Following Yesterday’s Bloodbath Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 27 August 2013 22:12
Yesterday, the NASDAQ Biotechnology index (NBI) dropped 3% in reaction to the selloff in the broader market.
Read more...
 
Dendreon: Too Little, Too Late? Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 26 August 2013 23:23
Dendreon (NASDAQ: DNDN)’s last two years of trading could be considered the stock market’s version of a slow motion train wreck.
Read more...
 
Ampio Momentum Continues After Positive Initial Phase III Data Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 26 August 2013 07:53
Recently presented data from a 329 patient Phase III trial for its lead candidate Ampion sent shares of Ampio Pharmaceuticals (NASDAQ: AMPE) sharply higher.
Read more...
 
ChemoCentryx Says Glaxo's Results from Study of Vercirnon Did Not Meet Primary Endpoint Print E-mail
By Staff and Wire Reports   
Friday, 23 August 2013 19:35
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 23, 2013.
Read more...
 
Nymox Issues Results on NX02-0018 Phase Trial; OncoMed Granted Patent for Methods of Treating Cancer Print E-mail
By Staff and Wire Reports   
Thursday, 22 August 2013 19:18
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 22, 2013.
Read more...
 
Boston Scientific Wins FDA Approval for IntellaTip MiFi XP Ablation Catheter; Incyte Issues Top-Line Results of Phase II PoC Trial of Ruxolitinib Print E-mail
By Staff and Wire Reports   
Wednesday, 21 August 2013 19:37
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 21, 2013.
Read more...
 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 23 of 55
BMR:1